JNJ-78934804 vs SPY003
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
JNJ-78934804
Developed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2028 · NCT07577856 (registry estimate)
No aligned efficacy figure on record for this race.
SPY003
Developed by Spyre Therapeutics
NCT07012395 · Phase 2 · recruiting
This was a randomized, quadruple-masked Phase 2 trial with 645 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-08. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Next expected readout: June 2027 · NCT07012395 (registry estimate)
Reported efficacy
Part A: Change in Robarts Histopathology Index (RHI) (Week 12); Part B: Percentage of participants with clinical remission (Week 12): Part A primary endpoint (week 12): Robarts Histopathology Index reduced 10.0 points from baseline (p<0.0001) (Spyre, 2026-09-08). (met)
Result source: NCT07012395
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | JNJ-78934804 | SPY003 |
|---|---|---|
| Clinical remission (induction) | —Trial running · NCT07577856 | —Not reported |
| Clinical remission (maintenance) | —Trial running · NCT07577856 | —Not reported |
| Clinical response (induction) | —Trial running · NCT07577856 | —Not reported |
| Endoscopic improvement (induction) | —Trial running · NCT07577856 | —Not reported |
| Corticosteroid-free remission (maintenance) | —Trial running · NCT07577856 | —Not reported |
Clinical remission (induction)
- JNJ-78934804
- —Trial running · NCT07577856
- SPY003
- —Not reported
Clinical remission (maintenance)
- JNJ-78934804
- —Trial running · NCT07577856
- SPY003
- —Not reported
Clinical response (induction)
- JNJ-78934804
- —Trial running · NCT07577856
- SPY003
- —Not reported
Endoscopic improvement (induction)
- JNJ-78934804
- —Trial running · NCT07577856
- SPY003
- —Not reported
Corticosteroid-free remission (maintenance)
- JNJ-78934804
- —Trial running · NCT07577856
- SPY003
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
JNJ-78934804: no structured comparison results are available for Ulcerative Colitis.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JNJ-78934804's landscape · SPY003's landscape